CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
Cincinnati, Ohio, United States and 19 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Dayton, Ohio, United States and 20 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Cincinnati, Ohio, United States and 76 other locations
(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...
Phase 1
Cincinnati, Ohio, United States and 23 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Dayton, Ohio, United States and 35 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Dayton, Ohio, United States and 230 other locations
for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...
Phase 3
Cincinnati, Ohio, United States and 60 other locations
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
Phase 3
Centerville, Ohio, United States of America and 312 other locations
Clinical trials
Research sites
Resources
Legal